AB9986
Anti-phospho-BRCA2 (Ser3291) Antibody
from rabbit, purified by affinity chromatography
Sign Into View Organizational & Contract Pricing
All Photos(3)
Synonym(s):
BRCA1/BRCA2-containing complex, subunit 2, Fanconi anemia group D1 protein 3, Fanconi anemia, complementation group D1, breast and ovarian cancer susceptibility gene, early onset, breast cancer 2 tumor suppressor, breast cancer 2, early onset, breast can
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rhesus macaque, horse, human
species reactivity (predicted by homology)
rat (based on 100% sequence homology), mouse (based on 100% sequence homology), hamster (based on 100% sequence homology), cat (based on 100% sequence homology), equine (based on 100% sequence homology), canine (based on 100% sequence homology), chimpanzee (based on 100% sequence homology), rhesus monkey (based on 100% sequence homology)
technique(s)
dot blot: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer3291)
Gene Information
human ... BRCA2(675)
General description
BRCA2 (Breast Cancer Type 2 susceptibility protein) is a tumor suppressor protein encoded by the BRCA2 gene.
The protein encoded by this gene plays a direct role in error-free double-strand break repair and homologous recombination. BRCA2 shares similarities with the tumor suppressor gene BRCA1. Inherited mutations in BRCA2 as well as BRCA1 are associated with an increased risk of developing breast or ovarian cancer. Although the structures of the BRCA1 and BRCA2 genes are very different, some functions are similar. The proteins made by both genes are essential for repairing damaged DNA and interact with the protein produced by the RAD51 gene. Together these three proteins play a role in maintaining the stability of the human genome and prevent dangerous gene rearrangements that can lead to the development of cancer.
The protein encoded by this gene plays a direct role in error-free double-strand break repair and homologous recombination. BRCA2 shares similarities with the tumor suppressor gene BRCA1. Inherited mutations in BRCA2 as well as BRCA1 are associated with an increased risk of developing breast or ovarian cancer. Although the structures of the BRCA1 and BRCA2 genes are very different, some functions are similar. The proteins made by both genes are essential for repairing damaged DNA and interact with the protein produced by the RAD51 gene. Together these three proteins play a role in maintaining the stability of the human genome and prevent dangerous gene rearrangements that can lead to the development of cancer.
Specificity
This antibody recognizes human BRCA2 phosphorylated at and around the internal domain surrounding Ser3291.
Immunogen
Epitope: Internal Domain surrounding Ser3291
KLH-conjugated linear peptide corresponding to human BRCA2 phosphorylated at and around the internal domain surrounding Ser3291.
Application
Anti-phospho-BRCA2 (Ser3291) Antibody is a rabbit polyclonal antibody for detection of phospho-BRCA2 (Ser3291), also known as BRCA1/BRCA2-containing complex subunit 2 & Fanconi anemia group D1 protein 3, has been validated in ICC, IHC, DB.
Immunocytochemistry Analysis: 1:500 dilution from a previous lot detected BRCA2 in MCF-7 cells.
Immunohistochemistry Analysis: 1:100 dilution from a previous lot detected BRCA2 in metastatic ductal carcinoma tissue.
Immunohistochemistry Analysis: 1:100 dilution from a previous lot detected BRCA2 in metastatic ductal carcinoma tissue.
Research Sub Category
Cell Cycle, DNA Replication & Repair
Oncoproteins
Cell Cycle, DNA Replication & Repair
Oncoproteins
Quality
Evaluated by Dot Blot in modified and non modified peptides of phosphorylated and non-phosphorlyated BRCA2.
Dot Blot Analysis: 2 µg/mL of this antibody detected BRCA2 in modified and non modified peptides of phosphorylated and non-phosphorlyated BRCA2.
Dot Blot Analysis: 2 µg/mL of this antibody detected BRCA2 in modified and non modified peptides of phosphorylated and non-phosphorlyated BRCA2.
Target description
~ 390 kDa
Analysis Note
Control
Modified and non modified peptides of phosphorylated and non-phosphorlyated BRCA2
Modified and non modified peptides of phosphorylated and non-phosphorlyated BRCA2
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lifeng Chen et al.
Clinical and translational medicine, 11(3), e341-e341 (2021-03-31)
PARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR- deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore
Gro Elise Rødland et al.
Frontiers in oncology, 9, 1301-1301 (2019-12-19)
The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). Herein we have
Sissel Hauge et al.
Oncotarget, 8(7), 10966-10979 (2016-12-29)
Recent studies have shown synergistic cytotoxic effects of simultaneous Chk1- and Wee1-inhibition. However, the mechanisms behind this synergy are not known. Here, we present a flow cytometry-based screen for compounds that cause increased DNA damage in S-phase when combined with
Gro Elise Rødland et al.
Cancers, 13(15) (2021-08-08)
Inhibitors of WEE1 and ATR kinases are considered promising for cancer treatment, either as monotherapy or in combination with chemo- or radiotherapy. Here, we addressed whether simultaneous inhibition of WEE1 and ATR might be advantageous. Effects of the WEE1 inhibitor
Grete Hasvold et al.
Molecular oncology, 10(5), 764-773 (2016-01-23)
Hypoxia promotes an aggressive tumor phenotype with increased genomic instability, partially due to downregulation of DNA repair pathways. However, genome stability is also surveilled by cell cycle checkpoints. An important issue is therefore whether hypoxia also can influence the DNA
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service